Madrigal Pharmaceuticals (MDGL) Change in Account Payables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Change in Account Payables data on file, last reported at $3.6 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at $3.6 million, up 332.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (down 59.24% YoY), and the FY2025 annual result was $5.3 million, down 66.07% from the prior year.
• Change in Account Payables slipped to $3.6 million in Q1 2026 per MDGL's latest filing, from $4.9 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $37.0 million in Q3 2024 and troughed at -$11.7 million in Q1 2023.
• A 5-year average of $1.8 million and a median of $1.4 million in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables sank 935.93% in 2023, then soared 3827.02% in 2024.
• A 5-year view of Change in Account Payables shows it stood at $5.3 million in 2022, then surged by 118.24% to $11.5 million in 2023, then tumbled by 120.58% to -$2.4 million in 2024, then jumped by 308.79% to $4.9 million in 2025, then dropped by 27.48% to $3.6 million in 2026.
• Business Quant data shows MDGL's Change in Account Payables at $3.6 million in Q1 2026, $4.9 million in Q4 2025, and $6.0 million in Q3 2025.